This patent discusses a probiotic agent aimed at improving hypertension, composed primarily of the Akkermansia muciniphila Akk11 and Lacticaseibacillus rhamnosus LRa05.

This probiotic composition, containing Akkermansia muciniphila Akk11 and Lactobacillus johnsonii LJ09, offers a novel and safe approach to managing hyperuricemia. Its synergistic action not only regulates uric acid levels but also protects the kidneys, reducing the risk of complications associated with high uric acid.

The synergy between WecStrainTM Bifidobacterium longum subsp. longum BL11 and WecStrainTM Lacticaseibacillus casei LC89 offers a novel, safe approach for managing mental health disorders through gut microbiota modulation.

he findings suggest that Akkermansia muciniphila Akk11 could serve as a powerful probiotic for managing metabolic health, specifically through the regulation of glucose and lipid metabolism.

This study evaluates the efficacy of probiotics, specifically WecStrainTM Lactobacillus salivarius LS97, WecLac® Lactobacillus paracasei LC86, and WecLac® Lactobacillus acidophilus LA85, as an adjunctive treatment for chronic periodontitis.

The emerging evidence linking Akkermansia muciniphila and their metabolite 3-IAA to the prevention and management of high myopia presents an exciting frontier in ocular health.